We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
EKF HbA1c Analyzer Assessment Success Presented at World Diabetes Congress
Product News

EKF HbA1c Analyzer Assessment Success Presented at World Diabetes Congress

EKF HbA1c Analyzer Assessment Success Presented at World Diabetes Congress
Product News

EKF HbA1c Analyzer Assessment Success Presented at World Diabetes Congress


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "EKF HbA1c Analyzer Assessment Success Presented at World Diabetes Congress"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

EKF Diagnostics has announced the successful assessment of its Quo-Test and Quo-Lab point-of-care HbA1c analyzers within the College of Medicine, Swansea University.

Dr Stephen Luzio, Associate Professor at the University, is giving a scientific poster presentation entitled ‘Assessment of two point-of-care analyzers for the determination of HbA1c’ at the World Diabetes Congress - International Diabetes Federation (IDF) 2013, Melbourne, Australia, 2nd to 6th December.

Glycated hemoglobin (HbA1c) is widely used as a means of monitoring diabetes control and has recently been recommended for use as a method of diabetes diagnosis. Measurement of HbA1c with point-of-care analyzers (POCT) has the advantage that samples can be determined on site, while a patient is still in the clinic.

Dr Luzio and his team have successfully compared EKF’s Quo-Test and Quo-Lab POCT HbA1c analyzers with an established laboratory HPLC method (D10, Biorad).

Dr Luzio’s scientific poster concludes that, “Use of the Quo-Test and Quo-Lab HbA1c POCT analyzers, provides a rapid, accurate and reproducible method of determination of HbA1c, with results comparable to an established laboratory HPLC method. Both have the benefit of being able to generate results immediately in the clinical setting, providing greater convenience to the patient.”

Also at IDF 2013, EKF Diagnostics will showcase its Quo-Lab and Quo-Test HbA1c analyzers, as well as the Biosen C-Line glucose and lactate analyzer at Stand A15. Both Quo-Test and Quo-Lab use boronate fluorescence quenching technology to measure HbA1c from just 4 µL of capillary or venous blood and deliver results within 4 minutes.

The Biosen C-Line analyzer is used to measure glucose and lactate precisely and quickly, from 25 seconds, in clinics, laboratories and sports medicine facilities around the world.

The aim of IDF is to advance diabetes care and prevention, and to establish a cure worldwide. IDF organizes the World Diabetes Congress on a biennial basis in differing global locations, to uniquely bring together healthcare professionals, researchers, policy makers, and people with diabetes, their carers and families.

Dr Luzio is also Portfolio Development Manager at the Diabetes Research Network which aims to promote existing strengths and potential in diabetes research and diabetes care in Wales.

Advertisement